CALT News and Press, Calliditas Therapeutics AB From 08/31/22

Summary Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo. Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, ...

Calliditas Therapeutics press release ( NASDAQ: CALT ): Q2 GAAP EPS of -SEK 3.62. Revenue of SEK 64M. Cash amounted to SEK 846.8M and SEK 709.3M as of June 30, 2022 and 2021 respectively. For further details see: Calliditas Therapeutics GAAP EPS of ...

Calliditas Therapeutics: Interim Report Q2, 2022 PR Newswire STOCKHOLM , Aug. 18, 2022 /PRNewswire/ -- European approval for Kinpeygo® "On May 19th , the European Medicines Agency (EMA) announced that it had adopted a positive opinion...

Results from the APOLLO-B study are due any day now and will significantly impact sentiment around ALNY shares, as well as the revenue potential of Onpattro. A clearly successful outcome could quadruple revenue, but it's possible that the trial could meet its primary outcome and fail ...

Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics PR Newswire Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment ...

The European Commission has approved Calliditas Therapeutics' ( NASDAQ: CALT ) Kinpeygo (budesonide) for the treatment of immunoglobulin A (IgA) nephropathy in adults. Shares are up 9% in Friday afternoon trading. The drug was developed under the name Nefe...

European Commission approves Kinpeygo® for adults with primary IgA nephropathy PR Newswire STOCKHOLM , July 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB ( Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that th...

Shares of Chinook Therapeutics have reacted well recently to a surprising secondary offering conducted at $14.00, providing it with additional capital for the commercialization of atrasentan. Although only one (likely) inferior therapy has been approved for the company’s initia...

NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to raise awareness of both the unique challenges faced by people living with IgA nephropathy and of the resources and support required to help them navigate their journey, Calliditas Therapeutics US, a wholly owne...

Calliditas Therapeutics (NASDAQ:CALT) filed with the SEC for an at-the market-program to sell up to $75M American depositary shares (ADSs) at market price from time to time. The number of ADSs to be sold under the open market sale agreement with Jefferies will depend upon the number...